Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KIT V559A + KIT N822I

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

Chr t(8;21) + KIT mutation (4)

Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation (4)

Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation (3)

KIT P577del + KIT W557Lfs*5 + KIT Y823D (2)

Chr inv(16)t(16;16) + KIT mutation (1)

KIT wild-type + SDHB deletion (1)

RUNX1-RUNX1T1 fusion + KIT D816 (1)

Chr t(8;21) + KIT mutation (4)

Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation (4)

Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation (3)

KIT P577del + KIT W557Lfs*5 + KIT Y823D (2)

Chr inv(16)t(16;16) + KIT mutation (1)

KIT wild-type + SDHB deletion (1)

RUNX1-RUNX1T1 fusion + KIT D816 (1)

›

4years

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma. (PubMed, Acta Derm Venereol)

No abstract available

4 years ago

Clinical • Journal

|

KIT (KIT proto-oncogene, receptor tyrosine kinase)

|

KIT V559A + KIT N822I

|

imatinib